Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 2.7% in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Vertex Pharmaceuticals (VRTX) reports results for the quarter ended September 2025. While this widely-known consensus ...

The Coral Triangle is an extremely biodiverse patch of ocean around the Philippines and Papua New Guinea. Its relatively murky waters appear to shield it against climate change — for now. When you ...

Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs as ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Eli Lilly has reached a deal to acquire SiteOne Therapeutics that would give it control of a non-opioid pain drug that would compete with a recently approved therapy from Vertex Pharma. The all-cash ...

The new Borea BR04 are designed to push the limits of performance When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Triangle has unveiled its ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday evening.

Vertex reported Q1 revenue and earnings that fell well short of what most investors were anticipating. Higher costs were primarily responsible for the hit to earnings. Despite the headwinds, Vertex ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A 30-story rezoning for Downtown ...

Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals ...

The stock has climbed 15.66% year-to-date, recovering from last year's volatility. With selling pressure creeping in, the question is whether this rally has legs, or if it’s time for a reset. Wall ...